Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Phase II SKYSCRAPER-05 trial.
Neoadjuvant tiragolumab (anti-TIGIT) + atezolizumab + chemo had RR 66%, MPR 51%, pCR 29% with 2y EFS rate 60%. 96% underwent surgical resection (93% R0).”
Title: SKYSCRAPER-05: A Phase 2 Study of Perioperative Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated, Locally Advanced, Resectable, Stage II‒IIIB Non-Small Cell Lung Cancer
Authors: Catherine A. Shu, Anthony W. Kim, Min Hee Hong, Alex Martinez Marti, Martin Frühe, Andrea Ferris, Harvey Pass, Bryan A. Chan, Saiama N. Waqar, Coen A. Bernaards, Namrata S. Patil, Jessie J. Hsu, Cristal Parsons, Sarah Troutman, Christina Matheny, Pao-Chen Li, Barbara Gitlitz, Enriqueta Felip
Read the full article.
Other articles featuring Stephen V Liu on OncoDaily.